European Digestive Cancer Days 26–27 September 2017
At the end of September, Prague hosts an international conference dedicated to prevention and treatment of colorectal cancer and other digestive cancers – European Digestive Cancer Days 2017. Presentations, press releases and short video from the conference was published.
 |
|
Related information:
Press Release
Annex to the Press Release
Additional Information to the Press Releas
Conference web pages
On September 2017 the international conference European Digestive Cancer Days (EDCD) was held in Prague. As one of its main objectives, the ECCD conference was promoting standardised colorectal cancer screening according to international best practices.
The EDCD conference was co-organised by Institute of Health Information and Statistics of the Czech Republic, United European Gastroenterology, Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses and Pavel Poc, Member of the European Parliament.
EDCD Conference was organised under the patronage of honourable:
- Mr. Vytenis Andriukaitis, European Commissioner for Health and Food Safety
- Mr. Pavel Poc, Member of the European Parliament
- Mr. Miloslav Ludvík, Minister of Health of the Czech Republic
- Mr. Rostislav Vyzula, Chair of the Health Committee of the Chamber of Deputies of the Czech Parliament
- Mr. Tomáš Zima, Rector of the Charles University
- Mrs. Alena Šteflová, Head of the WHO Country Office in the Czech Republic
- Mr. Štěpán Svačina, President of the Czech Medical Association of J. E. Purkyně
- Czech Society of Gastroenterology
- Czech Society for Oncology
We would like to offer to you presentations, press releases and short video from the conference. Our questions were answered by:
- RNDr. Ondřej Májek, Ph.D., Institute of Health Information and Statistics of the Czech Republic (time 0:05)
- Professor Stephen P. Halloran, MBE FRCPath - University of Surrey, NHS (time 0:47)
- ProfessorThierry Ponchon, United European Gastroenterology, Chair of the Public Affairs Committee (time 1:28)
Presentations
Workshop: Implementing innovations in colorectal cancer screening: Transition to quantitative immunochemical testing
- S. Halloran: Faecal testing in colorectal cancer screening: state of art
- O. Májek: Czech National Coordination Centre for Prevention of Serious Diseases: platform for systematic introduction of innovations to early disease detection
- S. Halloran: Implementation of population-based faecal occult blood testing and transition to immunochemical tests: experience from England
- B. Seifert: Role of primary care in population-based colorectal cancer screening: current situation and future prospects
- P. Kocna: Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech Republic
- O. Májek, Š. Suchánek: Quality-assured immunochemical testing – proposal for a pilot project in the Czech Republic
Pancreatic cancer: The main challenge
- P. Poc, L. Dušek: General introduction
- N. Malats: How to identify high-risk population
- S. Barbu: Burden, prevalence and prognosis of pancreatic cancer in 2017 (the presentation is not available yet)
- J. Rosendahl: Surveillance in patients with hereditary risks or chronic pancreatitis
- P. Frič, J. Škrha, A. Šedo, P. Bušek, M. Laclav, P. Škrha, B. Seifert, M. Zavoral:
- Detection of sporadic pancreatic cancer - time for change (presentation No. 1)
- Detection of sporadic pancreatic cancer - time for change (presentation No. 2)
- A. Stunt: Patient perspective
- J. Rosendahl: Conclusion: What do we need first?
Other digestive cancers: Next to be screened?
- T. Ponchon: Screening of Barrett: Is it cost-effective? Is there a high-risk population?
- P. Burra: Surveillance of hepatocarcinoma in cirrhotic patients
- M. Dinis Ribeiro: Is there a role for screening gastric carcinoma or preneoplastic lesions
CRC screening programmes: State of the art in Europe
- M. van Leerdam: CRC screening – State of the art in Western Europe
- M. Leja: CRC screening – State of the art in Eastern Europe
Differences between ongoing programmes
- E. Dekker: The Netherlands
- T. Seufferlein: Germany
- M. Løberg: Poland
State of the art in the Czech Republic – CRC screening: Czech experience in implementation
- L. Dušek: Role of comprehensive cancer care networks in organising colorectal cancer care: Experience from CANCON project
- O. Májek: Lessons learnt from cancer screening programmes as an example for establishing the Czech national coordination centre
- T. Grega, O. Májek: Practical challenges in establishing and running the Czech national colorectal cancer screening programme
Why and how to start a population based CRC screening programme?
- I. Lansdorp-Vogelaar: Cost-effectiveness analysis of a screening programme
- M. van Leerdam: Choice of screening method - factors to take into account
- I. Lansdorp-Vogelaar: Parameters for monitoring
- F. de Bels: Quality assurance and logistic organisation of a programme
Optimizing participation in ongoing CRC screening programmes
Why do we have different levels of participation in Europe?
- Influence of the programme design:
(a) Pro GP implication (F. de Bels)
(b) Cons GP implications (E. Dekker) - Influence of the population type – How to tackle inequalities! (S. Halloran)
- Influence of the message (J. Wilkes)
- Influence of the patient associations and/or influence of a champion (L. Colemont)
More photos in the photo gallery.
20. 10. 2017